News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Synta Pharmaceuticals Presents Results on Ganetespib and Hsp90 Inhibitor Class at the American Association for Cancer Research-European Organization for Research and Treatment of Cancer-National Cancer Institute Molecular Targets and Cancer Therapeutics Conference



11/15/2011 7:12:32 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that preclinical results presented at the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference show that ganetespib, a potent Hsp90 inhibitor, is highly effective in overcoming mechanisms of resistance in models of multiple oncogene addicted tumors.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES